BRIEF-Celator pharmaceuticals announces positive results in patients with flt3 mutation from phase 3 trial in high-risk acute myeloid leukemia

* Data from AML patients with a flt3 mutation demonstrated vyxeos had a statistically significant improvement in induction response rate
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.